EP2154958A4 - Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies - Google Patents

Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Info

Publication number
EP2154958A4
EP2154958A4 EP08747605A EP08747605A EP2154958A4 EP 2154958 A4 EP2154958 A4 EP 2154958A4 EP 08747605 A EP08747605 A EP 08747605A EP 08747605 A EP08747605 A EP 08747605A EP 2154958 A4 EP2154958 A4 EP 2154958A4
Authority
EP
European Patent Office
Prior art keywords
spla2
dyslipidemia
inhibitors
treatment
cardiovascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08747605A
Other languages
German (de)
French (fr)
Other versions
EP2154958A1 (en
Inventor
Joaquim Trias
Colin Hislop
Paul Truex
Heather Fraser
Debra Odink
Scott Chadwick
Kenneth Gould
Marian Mosior
Patrick Eacho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anthera Pharmaceuticals Inc
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of EP2154958A1 publication Critical patent/EP2154958A1/en
Publication of EP2154958A4 publication Critical patent/EP2154958A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP08747605A 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies Withdrawn EP2154958A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US96959107P 2007-08-31 2007-08-31
US87486907A 2007-10-18 2007-10-18
PCT/US2008/062577 WO2008137803A1 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Publications (2)

Publication Number Publication Date
EP2154958A1 EP2154958A1 (en) 2010-02-24
EP2154958A4 true EP2154958A4 (en) 2011-05-04

Family

ID=39943969

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08747605A Withdrawn EP2154958A4 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Country Status (8)

Country Link
EP (1) EP2154958A4 (en)
JP (1) JP2010526152A (en)
CN (1) CN101742907A (en)
AU (1) AU2008247451A1 (en)
BR (1) BRPI0811486A2 (en)
CA (1) CA2686157A1 (en)
EA (1) EA200971020A1 (en)
WO (1) WO2008137803A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395837A1 (en) * 2009-01-08 2011-12-21 Anthera Pharmaceuticals, Inc. Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
RU2483707C1 (en) * 2012-05-04 2013-06-10 Лира Талгатовна Гильмутдинова Method of sanatorium therapy of patients with metabolic syndrome and arterial hypertension with application of sulfide baths
CN115040508A (en) * 2022-07-28 2022-09-13 上海市同仁医院 Application of indole-3-acetaldehyde in preparing novel anti-obesity active preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
WO2002008189A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
EP1378246A1 (en) * 2001-03-19 2004-01-07 Shionogi & Co., Ltd. Remedies for arteriosclerosis
WO2007056281A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (en) * 1997-08-29 2000-02-01 THERAPEUTIC COMBINATIONS.
DE69921314T2 (en) * 1998-05-01 2006-02-09 Eli Lilly And Co., Indianapolis INHIBITOR ESTERS FOR sPLA 2
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
WO2002008189A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
EP1378246A1 (en) * 2001-03-19 2004-01-07 Shionogi & Co., Ltd. Remedies for arteriosclerosis
WO2007056281A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN W M ET AL: "Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A2", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 522, no. 1-3, 3 July 2002 (2002-07-03), pages 113 - 118, XP004369256, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(02)02907-1 *
MA J ET AL: "Are evidence-based cardiovascular prevention therapies being used? A review of aspirin and statin therapies", PREVENTION AND CONTROL, ELSEVIER, NL, vol. 1, no. 4, 1 December 2005 (2005-12-01), pages 285 - 295, XP025337910, ISSN: 1573-2088, [retrieved on 20051201], DOI: 10.1016/J.PRECON.2006.05.002 *
ROBINSON JENNIFER G ET AL: "Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, EXPERT REVIEWS LTD, GB, vol. 4, no. 4, 1 July 2006 (2006-07-01), pages 461 - 476, XP008134541, ISSN: 1744-8344, DOI: 10.1586/14779072.4.4.461 *
RODONDI NICOLAS ET AL: "Aspirin for the primary prevention of cardiovascular disease a comprehensive review", COMPREHENSIVE THERAPY, vol. 31, no. 3, October 2005 (2005-10-01), pages 186 - 193, XP002629623, ISSN: 0098-8243 *
See also references of WO2008137803A1 *
VERVOORDELDONK M J ET AL: "Aspirin inhibits expression of the interleukin-1beta-inducible group II phospholipase A2.", FEBS LETTERS 11 NOV 1996 LNKD- PUBMED:8941724, vol. 397, no. 1, 11 November 1996 (1996-11-11), pages 108 - 112, XP002629622, ISSN: 0014-5793 *
WIKLUND O ET AL: "Effects of simvastatin and atorvastatin on inflammation markers in plasma", JOURNAL OF INTERNAL MEDICINE, vol. 251, no. 4, April 2002 (2002-04-01), pages 338 - 347, XP002629621, ISSN: 0954-6820 *

Also Published As

Publication number Publication date
AU2008247451A1 (en) 2008-11-13
JP2010526152A (en) 2010-07-29
CN101742907A (en) 2010-06-16
BRPI0811486A2 (en) 2014-09-30
CA2686157A1 (en) 2008-11-13
WO2008137803A1 (en) 2008-11-13
EA200971020A1 (en) 2010-10-29
EP2154958A1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
HK1218256A1 (en) Methods of using mek inhibitors mek
IL240771A0 (en) Benzoxazole kinase inhibitors and methods of use
IL208719A0 (en) Inhibitors of protein kinases
EP2026843A4 (en) Therapeutic uses of inhibitors of rtp801l
RS58965B1 (en) Arginase inhibitors and methods of use
HK1160119A1 (en) Kinase inhibitors and methods of use
EP2379561A4 (en) Mlk inhibitors and methods of use
EP2252293A4 (en) Kinase inhibitors and methods of use
EP1981888A4 (en) Inhibitors of tyrosine kinases and uses thereof
SI2038265T1 (en) Human protein-tyrosine phosphatase inhibitors and methods of use
IL200611A0 (en) Inhibitors of serine proteases
EP2007383A4 (en) Inhibitors of protein prenyltransferases
IL208212A0 (en) Hydroxamate-based inhibitors of deacetylases b
ZA201006353B (en) Inhibitors of gm-csf and il-17 for therapy
IL201254A0 (en) 5 - oxo - isoxazoles as inhibitors of lipases and phospholipases
EP2205278A4 (en) Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors
EP2154958A4 (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies
EP2485750A4 (en) Peptide-based peroxidase inhibitors and methods of using same
EP2234493A4 (en) Therapeutic use of carboxyl ester lipase inhibitors
IL201897A0 (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies
IL212990A0 (en) Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
GB0719877D0 (en) Inhibitors of protein kinases
IL195722A0 (en) Therapeutic uses of inhibitors of rtp801l

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139282

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20110401

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20110325BHEP

Ipc: A61K 45/06 20060101ALI20110325BHEP

Ipc: A61K 31/404 20060101ALI20110325BHEP

Ipc: A61K 31/19 20060101ALI20110325BHEP

Ipc: A01N 37/10 20060101AFI20081127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120829

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139282

Country of ref document: HK